Antiobesity Medications for Older Adults—the New, the Good, the Bad, and the Unknown
Obesity · 2025-11 · 33 (S1) · 57-73
DOI: 10.1002/oby.70029 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Obesity, online erschienen am 08.10.2025. Verfasst von Anna Pendrey und 1 weiteren Autor:innen. Beteiligte Einrichtung: Department of Family Medicine, Indiana University School of Medicine, Indianapolis, Indiana, USA. Hauptthemen laut MEDLINE: Anti-Obesity Agents, Obesity. Die Arbeit wurde bisher 10-mal zitiert (Crossref) und nennt 86 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Themen: Gerontologische Pflege
Abstract (Originalsprache)
Objective
Obesity affects 42% of older adults, with rates continuing to rise. This a complex condition influenced by non‐modifiable as well as modifiable risk factors. The disease can be treated through modifications to diet, physical activity, and behavior and more recently through antiobesity medications (AOMs) and surgery. Treatment must be tailored to individual needs due to age‐related metabolic and physiological changes. This review aimed to identify the suitability of seven FDA‐approved AOMs in the treatment of obesity in older adults.
Methods
A review of AOMs was performed, focusing on their efficacy in weight loss, side effects, and potential health risks in older adults. Studies were selected to later evaluate the overall suitability and safety of these medications.
Results
AOMs can improve cardiovascular outcomes, hypertension, hyperlipidemia, metabolic liver disease, obstructive sleep apnea, and chronic kidney disease. Weight loss in older adults using AOMs is associated with an increased risk of sarcopenia.
Conclusions
From a policy standpoint, ensuring coverage of AOMs for older adults is critical, as these medications help reduce obesity‐related complications. However, increased participation in clinical trials is urgently needed to study the impact of quality of life and outcomes in older adults.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Family Medicine, Indiana University School of Medicine, Indianapolis, Indiana, USA.
ORCID-Profile: Anna Pendrey
Zitieren
APA
Pendrey, A., & Sevilla-Martir, J. (2025). Antiobesity Medications for Older Adults—the New, the Good, the Bad, and the Unknown. Obesity, 33(S1), 57-73. https://doi.org/10.1002/oby.70029
Vancouver
Pendrey A, Sevilla-Martir J. Antiobesity Medications for Older Adults—the New, the Good, the Bad, and the Unknown. Obesity. 2025;33(S1):57-73. doi:10.1002/oby.70029
BibTeX
@article{Pendrey2025,
author = {Pendrey, Anna and Sevilla-Martir, Javier},
title = {Antiobesity Medications for Older Adults—the New, the Good, the Bad, and the Unknown},
journal = {Obesity},
year = {2025},
volume = {33},
number = {S1},
pages = {57--73},
doi = {10.1002/oby.70029}
}
EUVIMED